RT Journal Article
T1 Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases
A1 Decara, Juan
A1 Rivera, Patricia
A1 Lopez-Gambero, Antonio Jesus
A1 Serrano, Antonia
A1 Pavon, Francisco Javier
A1 Baixeras, Elena
A1 Rodriguez-de-Fonseca, Fernando
A1 Suarez, Juan
K1 PPARa
K1 PPARg
K1 PPARb/d
K1 Inflammatory bowel diseases
K1 Ulcerative colitis
K1 Crohn's disease
AB The peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor proteins that promote ligand-dependent transcription of target genes that regulate energy production, lipid metabolism, and inflammation. The PPAR superfamily comprises three subtypes, PPARα, PPARγ, and PPARβ/δ, with differential tissue distributions. In addition to their different roles in the regulation of energy balance and carbohydrate and lipid metabolism, an emerging function of PPARs includes normal homeostasis of intestinal tissue. PPARα activation represses NF-κB signaling, which decreases the inflammatory cytokine production by different cell types, while PPARγ ligands can inhibit activation of macrophages and the production of inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, and Il-1β. In this regard, the anti-inflammatory responses induced by PPAR activation might restore physiopathological imbalances associated with inflammatory bowel diseases (IBD). Thus, PPARs and their ligands have important therapeutic potential. This review briefly discusses the roles of PPARs in the physiopathology and therapies of the most important IBDs, ulcerative colitis (UC), and Crohn's disease (CD), as well some new experimental compounds with PPAR activity as promising drugs for IBD treatment.
PB Frontiers
YR 2020
FD 2020-05-27
LK http://hdl.handle.net/10668/3629
UL http://hdl.handle.net/10668/3629
LA en
NO Decara J, Rivera P, López-Gambero AJ, Serrano A, Pavón FJ, Baixeras E, et al. Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases. Front Pharmacol. 2020 May 27;11:730
DS RISalud
RD Apr 9, 2025